PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

Roche bets big on off-the-shelf cancer cell therapy with Adaptimmune deal

Adaptimmune, like companies such as Bluebird Bio and Cellectis, remains one of the more prominent independent developers of cancer cell therapies. Early pioneers Kite Therapeutics and Juno Therapeutics were snapped up by Gilead and Celgene, respectively, with the Juno portfolio now in the hands of Bristol Myers Squibb.

The treatments Kite and Juno developed and their acquirers now sell, however, are logistically complex. They, as well as another drug from Novartis, require a laborious multi-week production process. Side effects can also be severe, meaning patients have to stay in or near a specialized hospital after the engineered cells are reinfused back into the body.

Adaptimmune has been developing such “autologous” treatments, too. But unlike many of its peers, the biotech has focused on solid tumours, a tougher cell therapy target. Alongside that effort has been an emerging plan to develop off-the-shelf, or “allogeneic” therapies, that could bypass many of the problems autologous treatments face if they prove safe and effective in clinical testing.

Adaptimmune already has a long-running partnership in place with GlaxoSmithKline for its autologous work. But Roche has taken a significant interest in its off-the-shelf research, a notable investment from a company that, while known for its cancer business, had yet to make a large bet on cell therapy.

The deal calls for Adaptimmune to develop T cell-based treatments using its in-house technology, which reprograms donor stem cells that can mature into other types of cells. Roche will be responsible for engineering the receptors on those cells that can latch onto tumours, as well as helping out with development and commercialization.

The additional revenue will help Adaptimmune sustain operations through early 2024 as it attempts to push forward seven clinical programs. The company had $285 million in cash and securities as of June 30, a sum that had declined by $83 million through the first six months of 2021.

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40